DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody

 DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking
                                   Antibody

PR Newswire

PARSIPPANY, N.J., April 22, 2013

PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ --DSM Pharmaceutical Products,
the custom manufacturing and technology business of Royal DSM (NYSE, Euronext:
DSM KON), announced today that it has signed an agreement with venture capital
funded DecImmune Therapeutics of Cambridge, Massachusetts, USA

The agreement covers the initiation of development activities by DSM for
DecImmune's lead monoclonal antibody program. The initial development will be
performed at DSM Biologics' Groningen, the Netherlands, facility, with the
objective of progressing manufacture of clinical trial material to DSM's
facility in Brisbane, Australia. DecImmune's proprietary antibody therapeutic
is designed to reduce tissue damage and improve ventricular function
associated with myocardial infarction. Regaining full function after a heart
attack can be complicated by irreversible tissue damage and scar formation
that leads to a significant loss in cardiac pumping efficiency. In a range of
experimental models, DecImmune has shown that it is possible to reduce damage
to heart tissue by using their proprietary therapeutic antibody.In these
models the reduction in damage to heart tissue results in pumping efficiency
returning to normal levels. DecImmune is also investigating this targeted
approach to reduce tissue damage for a range of other acute and chronic
post-injury settings.

Karen King, President of DSM Biologics, commented "We are delighted to be
working with DecImmune on their exciting project. DSM is committed to
delivering our clients around the world the highest quality solutions and
services." DSM Biologics, a business unit of DSM Pharmaceutical Products,
focusesonoptimizing mammalian-based biopharmaceutical manufacturing through
its unique set of technologies and expertise. In addition to an R&D and
manufacturing site in Groningen, the Netherlands, DSM is starting up
operations in 2013 in Brisbane, Australia, with the support of the Government
of Queensland and the Commonwealth of Australia. The Brisbane facility is
DSM's prototype 'biologics plant of the future' for the production of
biopharmaceuticals employing DSM's proprietary technologies. DSM's
technologies drive down cost, processing times, scale-up risk and capital
requirements to meet market demand for developing cost-effective, lifesaving
medications.

"Partnering with DSM for its antibody process development and manufacturing
enables DecImmune to move rapidly through late preclinical studies and into
clinical development. DSM's experience, capacity, and technical expertise in
Groningen and Brisbane meet the full range of DecImmune's manufacturing needs.
We look forward to working with one of the world's leading science-based
companies as our manufacturing partner," stated Christopher K. Mirabelli,
Ph.D., President and CEO of DecImmune and Managing Director at HealthCare
Ventures, DecImmune's lead investor.

"In line with DSM's stated strategy, and fulfillment of its commitment to
bring manufacturing and technological excellence to the global
biopharmaceutical market, this agreement with DecImmune represents the best of
what DSM is doing to help our customers serve critical needs in healthcare.
The combination of the Groningen and Brisbane operations will support
DecImmune throughout the development process and on to clinical trials."
declared Alexander Wessels, President and CEO of DSM Pharmaceutical Products.

David Hughes, CEO of BioPharmaceuticals Australia (BPA), said "We have always
been of the view that success for this facility would come from leveraging
both local and global demand. BPA's ongoing partnership with DSM brings a
wealth of expertise to the region. Brisbane is home to sophisticated
biomanufacturing technology and this contract with DecImmune bolsters the city
as an internationally-recognized location for biotherapeutic development."
BPA, an industry-development company owned by the Queensland State Government,
put together the partnering deal with DSM Biologics, and is currently project
managing the final stages of the construction of the new state-of-the-art
facility in cooperation with DSM Biologics.

Financial terms were not disclosed.

DecImmune Therapeutics
DecImmune Therapeutics was founded by Michael Carroll Ph.D. (Boston Children's
Hospital, Harvard Medical School), and Francis Moore Jr. MD (Brigham and
Women's Hospital, Harvard Medical School). Drs. Moore and Carroll discovered
the non-muscle myosin heavy chain II ("N2") cascade that is initiated
following vascular injury. Shortly after expression of the N2 neoepitope on
the cell surface in the vasculature, IgM components of the innate immune
pathway bind and initiate the cascade responsible for localized tissue
damage. DecImmune is developing an antibody-based therapeutic that can
prevent tissue damage and preserve organ function by inhibiting activation of
the N2 neoepitope in the innate autoimmune pathway. More information can be
found at www.decimmune.com.

DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 23,500 employees deliver annual net sales of around € 9 billion. The
company is listed on NYSE Euronext. More information can be found at
www.dsmbiologics.com and www.dsm.com

Forward-looking statements
This press release may contain forward-looking statements with respect to
DSM's future (financial) performance and position. Such statements are based
on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements
involve certain risks and uncertainties that are difficult to predict and
therefore it should be understood that many factors can cause actual
performance and position to differ materially from these statements. DSM has
no obligation to update the statements contained in this press release, unless
required by law. The English language version of the press release is leading.



For more information:
Guy Tiene                              Karen King
Director, Marketing and Communications President
DSM Pharmaceutical Products            DSM Biologics
tel. +1 973 257 8160                  tel. +1 973 257 8427
email guy.tiene@dsm.com              email karen.king@dsm.com 



SOURCE DSM Pharmaceutical Products

Website: http://www.dsm.com
 
Press spacebar to pause and continue. Press esc to stop.